These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37148240)

  • 1. Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.
    Kolind S; Gaetano L; Assemlal HE; Bernasconi C; Bonati U; Elliott C; Hagenbuch N; Magon S; Arnold DL; Traboulsee A
    Mult Scler; 2023 May; 29(6):741-747. PubMed ID: 37148240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
    Arnold DL; Sprenger T; Bar-Or A; Wolinsky JS; Kappos L; Kolind S; Bonati U; Magon S; van Beek J; Koendgen H; Bortolami O; Bernasconi C; Gaetano L; Traboulsee A
    Mult Scler; 2022 Oct; 28(12):1927-1936. PubMed ID: 35672926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
    N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
    Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
    JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
    Samjoo IA; Klotz L; Giovannoni G; Drudge C; Haltner A; Worthington E; Zhao M; Brennan R; Häring DA; Cameron C; Adlard N
    Mult Scler Relat Disord; 2022 Oct; 66():104031. PubMed ID: 35841716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
    Bar-Or A; Thanei GA; Harp C; Bernasconi C; Bonati U; Cross AH; Fischer S; Gaetano L; Hauser SL; Hendricks R; Kappos L; Kuhle J; Leppert D; Model F; Sauter A; Koendgen H; Jia X; Herman AE
    EBioMedicine; 2023 Jul; 93():104662. PubMed ID: 37354600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
    Turner B; Cree BAC; Kappos L; Montalban X; Papeix C; Wolinsky JS; Buffels R; Fiore D; Garren H; Han J; Hauser SL
    J Neurol; 2019 May; 266(5):1182-1193. PubMed ID: 30820738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Joint MRI T1 Unenhancing and Contrast-enhancing Multiple Sclerosis Lesion Segmentation with Deep Learning in OPERA Trials.
    Krishnan AP; Song Z; Clayton D; Gaetano L; Jia X; de Crespigny A; Bengtsson T; Carano RAD
    Radiology; 2022 Mar; 302(3):662-673. PubMed ID: 34904871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
    Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
    Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
    Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
    Hauser SL; Bar-Or A; Weber MS; Kletzl H; Günther A; Manfrini M; Model F; Mercier F; Petry C; Wing Q; Koendgen H; Smith T; Kappos L
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36792367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study.
    Rodriguez de Antonio LA; Cuberta-Gonzalez I; Garcia-Castañon I; Oreja-Guevara C
    Mult Scler Relat Disord; 2023 Jan; 69():104441. PubMed ID: 36493559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO.
    Gibiansky E; Petry C; Mercier F; Günther A; Herman A; Kappos L; Hauser S; Yamamoto Y; Wang Q; Model F; Kletzl H
    Br J Clin Pharmacol; 2021 Jun; 87(6):2511-2520. PubMed ID: 33202059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
    Hauser SL; Kappos L; Arnold DL; Bar-Or A; Brochet B; Naismith RT; Traboulsee A; Wolinsky JS; Belachew S; Koendgen H; Levesque V; Manfrini M; Model F; Hubeaux S; Mehta L; Montalban X
    Neurology; 2020 Sep; 95(13):e1854-e1867. PubMed ID: 32690791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
    Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
    Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a.
    Kolind S; Abel S; Taylor C; Tam R; Laule C; Li DKB; Garren H; Gaetano L; Bernasconi C; Clayton D; Vavasour I; Traboulsee A
    Neuroimage Clin; 2022; 35():103109. PubMed ID: 35878575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
    McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
    Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.
    Giovannoni G; Kappos L; de Seze J; Hauser SL; Overell J; Koendgen H; Manfrini M; Wang Q; Wolinsky JS
    Eur J Neurol; 2022 Apr; 29(4):1238-1242. PubMed ID: 33724637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience.
    Guerrieri S; Bucca C; Nozzolillo A; Genchi A; Zanetta C; Cetta I; Rugarli G; Gattuso I; Azzimonti M; Rocca MA; Moiola L; Filippi M;
    Eur J Neurol; 2023 Sep; 30(9):2859-2864. PubMed ID: 37227923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review.
    Montalban X; Matthews PM; Simpson A; Petrie JL; Sammon C; Ramagopalan S; Disanto G; Kuhle J
    Ann Clin Transl Neurol; 2023 Mar; 10(3):302-311. PubMed ID: 36728340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.